🔴 ACADIA Pharmaceuticals is trading 4.1% down today after Phase 2 RADIANT study narrowly misses primary endpoint

ACADIA Pharmaceuticals is trading 4.1% down at $21.27 after September 24, 2026, Phase 2 RADIANT results for remlifanserin narrowly missed the primary endpoint (p=0.0603; threshold 0.05). - The 60 mg dose achieved statistical significance on a key secondary measure; investors appear focused on the primary-endpoint miss. - ACADIA plans to advance the program into Phase 3. - The stock is down from its $22.18 September 24 close; it fell 12.78% that session, and trading-volume data was unavailable.